Xention raises £8 million to advance atrial fibrillation work
This article was originally published in Scrip
Executive Summary
Xention, a Cambridge,UK-based biopharmaceutical company has raised £8 million in series D financing round to further its work in ion channel targets and atrial fibrillation in particular.